Other Events ·
AstraZeneca entered into an exclusive global license agreement with Dizal Pharmaceutical Co., Ltd. to acquire…
AZNCFAstrazeneca PLC
AstraZeneca entered into an exclusive global license agreement with Dizal Pharmaceutical Co., Ltd. to acquire worldwide rights to develop and commercialize Zegfrovy (sunvozertinib), a novel oral EGFR inhibitor for lung cancer. The transaction involves an upfront payment of $600 million and potential milestone payments of up to $900 million, plus tiered royalties on global sales. The deal is expected to close in the second half of 2026. AstraZeneca is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals.